NCT01639092View on ClinicalTrials.gov

Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 28, 2012

Primary Completion Date

March 29, 2018

Study Completion Date

March 29, 2018

Conditions
Chronic Viral Hepatitis B Without Delta-agent
Interventions
DRUG

Tenofovir

Tenofovir 300mg Daily Oral

DRUG

Tenofovir

Tenofovir 300mg Daily Oral

DRUG

Entecavir

Entecavir 1 mg daily Oral

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Konkuk University Medical Center

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Seoul National University Hospital

OTHER

lead

Asan Medical Center

OTHER

NCT01639092 - Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B | Biotech Hunter | Biotech Hunter